David B. Roberts Sells 5,025 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts sold 5,025 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The sale was disclosed in a legal filing with the SEC, which is available through this link.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $76.00 on Friday. The company has a market cap of $1.71 billion, a P/E ratio of 50.33, a P/E/G ratio of 2.99 and a beta of 0.88. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $76.24. The firm has a 50-day moving average of $66.67 and a 200-day moving average of $59.46.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.05. The company had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.27 earnings per share. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Analysts Set New Price Targets

LMAT has been the subject of several recent research reports. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp started coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research raised their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their target price for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Finally, JMP Securities raised their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $73.83.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in LMAT. Shaker Investments LLC OH boosted its stake in LeMaitre Vascular by 1.3% in the first quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock valued at $906,000 after acquiring an additional 169 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in LeMaitre Vascular by 0.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after purchasing an additional 187 shares during the last quarter. Riverwater Partners LLC grew its holdings in LeMaitre Vascular by 2.5% during the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 198 shares during the period. Albion Financial Group UT increased its position in LeMaitre Vascular by 5.6% in the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 212 shares during the last quarter. Finally, Texas Permanent School Fund Corp raised its stake in shares of LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after buying an additional 225 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.